AgingResearch.NewsJoin free

Phase 2Active, not recruitingAge-related condition

Study of SPG302 in Adult Participants With Mild-to-Moderate Alzheimer's Disease (AD)

A Phase 2, Randomized, Placebo-controlled, Double-Blind Multicenter Study to Assess the Safety, Tolerability, and Pharmacodynamics (PD) in Adult Participants With Mild-to Moderate Alzheimer's Disease (AD) Administered SPG302

Sponsor
Spinogenix (Industry)
Enrolment
24 enrolled
Conditions
Alzheimer Disease
Interventions
SPG302; Placebo
Ages
adults, older adults
Registry
NCT06427668

Full record on ClinicalTrials.gov

From the registry

This phase 2 study will evaluate the safety, tolerability, clinical efficacy, pharmacokinetics, and pharmacodynamics of SPG302 in adult participants with mild-to-moderate AD.

Primary outcomes

  • Change in Electroencephalogram (EEG) at resting state and at auditory evoked P300 from baseline to endpoint
  • Change in Alzheimer's Disease Assessment Scale-Cog (ADAS-COG) total score from baseline to endpoint
  • Change in Mini-Mental State Examination (MMSE) from baseline to endpoint
  • C-SSRS (Columbia Suicide Severity Rating Scale)

History

  1. Study completion

  2. Primary completion

  3. Last registry update

  4. Started

  5. Registered